Phosphate Binders Offer No Short-Term Mortality Benefit
ATLANTA—Phosphate binder use by chronic kidney disease (CKD) patients does not lower their risk of death, according to a study presented at the American Society of Nephrology's Kidney Week 2013 meeting.
Sankar D. Navaneethan, MD, and colleagues at Cleveland Clinic studied 939 CKD patients on phosphate binders (238 on non-calcium-based binders and 701 on calcium-based binders) who were propensity matched to those not on phosphate binders.
Phosphate binder use was not significantly associated with mortality among patients who took the drugs for at least six months. Patients who took a binder for one year had a non-significant 15% reduced mortality risk. Results showed no difference in death risk between calcium-based and non-calcium-based binders.
Additionally, the study found that each 5 kg/m2 increment in body mass index, 1 mg/dL increment in serum phosphorus, and 1 mg/dL increment in serum calcium was associated with a 12%, 35%, and 35% increased likelihood of being prescribed a non-calcium-based binder.